Author Archives: admin


Stem Cell Clinic > Articles by: admin

Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)

By Global News Feed

Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of Translational Science, will present at the Thirteenth London International Cough Symposium taking place July 18 - 19, 2024 at Imperial College in London, U.K.

Follow this link:
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)

FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows Superiority Over Flu Shot Alone

By Global News Feed

– Findings reported today in the journal Lancet Infectious Diseases– Study shows synergistic immunological response generated by M2SR and Fluzone High Dose vaccine when used in combination in the highly vulnerable 65-85 years old population – Results suggest approach could be used for vaccination against future influenza pandemics such as H5N1

Excerpt from:
FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows Superiority Over Flu Shot Alone

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

SAN FRANCISCO, July 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 125,000 shares of the Company’s common stock to six new employees (the “Inducement Grants”) on July 9, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).

Follow this link:
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Clene to Present at the Emerging Growth Conference

By Global News Feed

SALT LAKE CITY, July 12, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference.

More:
Clene to Present at the Emerging Growth Conference

Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference

By Global News Feed

Vancouver, Canada, July 12, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces its participation in the upcoming Psychedelic Medicine – Israel 2024 conference. This event will take place in Tel Aviv, Israel from July 28th to 30th, bringing together leading experts and researchers from around the world in the field of psychedelic medicine.

Read more:
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference

Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

By Embryonic Stem Cells

SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that China’s National Medical Products Administration (“NMPA”) has approved Gyre Pharmaceuticals’ (Gyre’s indirectly controlled subsidiary) avatrombopag maleate tablets for the treatment of thrombocytopenia (“TP”) associated with chronic liver disease (“CLD”) in adult patients undergoing elective diagnostics procedures or therapy. TP is the most common hematologic complication in patients with CLD and can be life threatening in severe cases.

Read more:
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

→←